FY 2020 FINANCIAL RESULTS AND CORPORATE UPDATE

March 4, 2021

DISCLAIMER

This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. By receiving this presentation and/or attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations. This presentation is being made only to, and is directed only at, (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the United Kingdom Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) (the “Order”); (ii) high net worth bodies corporate, unincorporated associations, partnerships and trustees of high value trusts as described in Article 49(2)(a)-(d) of the Order; (iii) “overseas recipients” as defined in Article 12 of the Order; (iv) persons in member states of the European Economic Area (the “EEA”) who are qualified investors, as defined in the Prospectus Regulation (Regulation (EU) 2017/1129) (as amended); (v) qualified institutional buyers in the United States as defined in Rule 144A of the United States Securities Act of 1933 as amended (the “Securities Act”); or (vi) persons to whom it would otherwise be lawful to distribute it (all such persons being “Relevant Persons”). Persons who receive this communication (other than Relevant Persons) should not rely on or act upon the contents of this presentation and should return this document immediately. This presentation is being directed only at Relevant Persons and any investment or investment activity to which this presentation relates will be engaged in only with Relevant Persons. This presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the “Group”) or in any other entity, nor shall this presentation or any part of it, or the fact of its presentation, form the basis of, or be relied on in connection with, any contract or investment activity (including within the meaning specified in section 21 of the United Kingdom Financial Services and Markets Act 2000), nor does it constitute a recommendation regarding the securities of the Group. Securities of the abovementioned persons or any of their respective affiliates have not been registered under United States securities laws and may not be offered or sold in the United States absent registration under such laws absent registration or an applicable exemption from registration requirements. Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Company’s securities, cannot be relied on as a guide to future performance. Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial adviser or independent legal counsel. Neither this presentation nor any information contained in this presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the presentation to any other person in the United States, Canada, Australia, Japan or any other jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation. Recipients of this presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you. No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discussed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this presentation. No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this presentation or any other written or oral information which has been or may be made available. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to the presentation. No reliance whatsoever may be placed on the presentation for any purpose. The Company’s shares are currently admitted to trading on public exchanges and, therefore, certain of the information in this presentation could constitute inside information and/or price sensitive information. By accepting this presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws. The information contained in this presentation has not been independently verified.

The Amryt logo, Myalept®, Myalepta®, Juxtapid®, Lojuxta®, Filsuvez® and other trademarks or service marks of Amryt appearing in this presentation are the property of Amryt. This presentation includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this presentation appear without the ®, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Filsuvez® (Oleogel-S10/birch triterpenes/formerly known as AP101) is currently an investigational product and has not received regulatory approval by the FDA or EMA. Elements of this presentation only apply in the event that Filsuvez® is approved by the appropriate regulatory authorities.

FORWARD-LOOKING STATEMENTS

The information in this presentation includes forward-looking statements, made in good faith, which are based on the Group's or, as appropriate, the Group's directors' current expectations and projections about future events. These forward-looking statements may be identified by the use of forward-looking terminology including, but not limited to, the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussion of the Group's strategy, plans, operations, financial performance and condition, objectives, goals, future events or intentions. These forward-looking statements, as well as those included in any other material discussed at the meeting, are subject to risks, uncertainties and assumptions about the Group and investments many of which are outside of the Group's control, including, among other things, the development of its business, the trends in its operating industry, changing economic, financial, or other market conditions and future capital expenditures. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may differ materially from those indicated in these statements. Forward-looking statements may, and often do, materially differ from actual results. Thus, these forward-looking statements should be treated with caution and the recipients of the presentation should not place undue reliance on any forward-looking statements. None of the future projections, expectations, estimates or prospects or any other statements contained in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the Company's future financial performance. The Company's past performance cannot be relied on as a guide to future performance. Any forward looking-statements are made as of the date hereof. The information and opinions contained in this presentation and any other material discussed verbally are provided as at the date of this presentation and are subject to verification, completion and change without notice.

The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified. Subject to obligations under the AIM Rules for Companies published by London Stock Exchange plc, the Securities and Exchange Commission ("SEC") and the Market Abuse Regulation (Regulation (EU) 596/2014) (each as amended from time to time), none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise. In giving this presentation none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent. Certain industry and market data contained in this presentation has been obtained from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company's own internal case studies, research and estimates based on the knowledge and experience of the Company's management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice. Risks and uncertainties affecting the Company are outlined further in the Company SEC filings.

This presentation may include certain combined or pro forma financial information for the Company. Such combined or pro forma financial information is preliminary in nature, remains subject to change and is provided solely for illustrative purposes. No reliance should be placed on the combined or pro forma financial information contained in this presentation. By requesting to receive and reviewing this document, you agree to be bound by the foregoing limitations and conditions and, in particular, will be deemed to have represented, warranted and undertaken that you have read and agree to comply with the contents of this disclaimer.

TRANSFORMATIONAL PERIOD OF PERFORMANCE & GROWTH

SUCCESSFUL EXECUTION & INTEGRATION

- Aegerion acquired (Sep 19') - successfully integrated by Q1 2020
- Revenues increased 18.5% YoY to $182.6M
  - Metreleptin revenues grew 25% and lomitapide increased by 10%
- EBITDA $30.4M in FY 2020
- Strong cash generation of $26.9M in 2020. Excl. DoJ fines - $42.6M
- 5 quarters of consistent performance & growth ahead of expectations
- Significant market expansion in existing & new territories for both metreleptin and lomitapide
- Multiple positive results in national reimbursement discussions
- Successfully developing life-cycle management opportunities
- Nasdaq listing in July 2020
- First ever positive Phase 3 readout in EB - primary endpoint met
- Issuing positive FY 2021 revenue guidance of $200M - $205M



* Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2019. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out-licencing of lomitapide (Juxtapid®) to Recordati, which occurred in February 2019, (ii) exclude up-front payments from Recordati in 2019, and (iii) include a 22.5% royalty on Japanese sales of lomitapide (Juxtapid®) from 1 January 2019, as if the Recordati agreement were in place from that date.

METRELEPTIN

GLOBAL REVENUES OF **$107M -** REPRESENTING **25%** GROWTH VERSUS 2019



- US contributed 57% of global metreleptin revenues in 2020, EMEA contributed 30%
- EMEA (approved July 2018) still in launch mode
- Significant value inflection points through ongoing national reimbursement discussions
- Significant periodic LATAM orders

Label Expansion Initiatives

- Seek label expansion to include the treatment of partial lipodystrophy (PL) in US
- Management estimates that adding PL would effectively double the size of the US addressable market from $140M to $280M

* Unaudited combined revenues for 2018 and 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2018

LOMITAPIDE

GLOBAL REVENUES OF **$75M** - REPRESENTING **10%** GROWTH VERSUS 2019



- US contributed 50% of global lomitapide revenues in 2020, EMEA contributed 35%
- EMEA 38% YoY growth driven by UK launch post reimbursement, France launch post reimbursement and GCC

Label Expansion Initiatives

- Pediatric HoFH: Phase 3 data expected in H1 2022
- FCS: Physician sponsored 18 patient study underway in Northern Italy. Management estimates that label expansion into FCS would potentially double the addressable market

* Unaudited combined revenues for 2018 and 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2018. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out-licencing of Juxtapid® to Recordati, which occurred in February 2019, (ii) exclude up-front payments from Recordati in 2019, and (iii) include a 22.5% royalty on Japanese sales of Juxtapid® from 1 January 2018, as if the Recordati agreement were in place from that date.

EASE TRIAL MET ITS PRIMARY ENDPOINT



44% increase in target wound closure with Oleogel-S10 vs control gel

Relative risk [95%CI], 1.44 [1.01, 2.05]

Odds ratio [95%CI], 1.84 [1.02, 3.30]

- Largest ever Phase 3 RCT [1] performed in EB
- The primary endpoint demonstrated a statistically significant acceleration of target wound healing by day 45 in patients treated with Oleogel-S10 vs control gel (p=0.013)[2]
  - The RDEB[3] sub-group was observed to experience a greater benefit when treated with Oleogel-S10 than the overall population (nominal p=0.008)
- Favourable trends were evident among secondary endpoints including procedural pain, change in EBDASI [3] score and BSAP [3]
- Oleogel-S10 had an acceptable safety profile and was well tolerated when compared with control gel

Oleogel-S10 represents a potentially important advancement for patients and families living with this intractable skin disease

1. Randomised Controlled Trial
2. Pre-specified adjustment to account for IDMC interim sample size re-estimation;
3. RDEB; Recessive Dystrophic EB; EBDASI, Epidermolysis Bullosa Disease Activity and Scarring Index; BSAP, Body Surface Area Percentage

RDEB SUBGROUP DRIVES PRIMARY ENDPOINT TREATMENT EFFECT

Relative risk [95% CI], 1.72 [1.14, 2.59]

Odds ratio [95% CI], 2.52 [1.27, 4.98]



72% increase in target wound closure in RDEB patients with Oleogel-S10 vs control gel

* Nominal P values

** RDEB, Recessive Dystrophic EB; DDEB, Dominant Dystrophic EB; JEB, Junctional EB

OLEOGEL-S10 - US & EUROPEAN ANTICIPATED REGULATORY TIMELINES

NDA TIMELINE – FDA – 6 MONTH PRIORITY REVIEW AND ROLLING NDA

2020

January — **December**

- **Apr** - Type C meeting completed
- **Jun** - Module 3 CMC request for priority review submitted
- **Sept** – Positive Top Line Phase 3 Results w/ primary endpoint met
- **Dec**- pre-NDA meeting

2021

January — **December**

- **Mar** - Initial submission
- **May** - Filing Date
- **Nov** - Anticipated Approval Date
- **Nov** – Priority Review Voucher*

MAA TIMELINE – EMA – ACCELERATED ASSESSMENT

2020

January — **December**

- **Jun** – MAA Letter of Intent submitted to EMA
- **Sep** – Rapporteurs assigned by CHMP
- **Nov** – MAA Pre-submission meetings
- **Dec** – Accelerated Assessment request to CHMP

2021

January — **December**

- **Mar** - Initial submission
- **Jul** - List of Questions (LoQ) received
- **Sep** - Submission of responses to LoQ
- **Nov** - List of Outstanding Issues (LoOI) received and responses submitted
- **Dec** - CHMP Opinion

* Eligibility for PRV assumes Priority Review awarded for Oleogel-S10 NDA

AP103 - BUILDING AN EB FRANCHISE - GENE THERAPY PLATFORM

- Novel polymer-based topical gene therapy delivery platform
- AP103, our first product candidate utilizing this platform, is being studied for DEB
- Granted Orphan Drug Designation by FDA and EMA in 2020
- Potential use for the treatment of other genetic diseases



AMRYT PHARMA

AP103 - REGULATORY & DEVELOPMENT TIMELINE

Orphan Drug Designation

- ✓ FDA: For the treatment of dystrophic epidermolysis bullosa: 21 Dec 2020
- ✓ EMA: Treatment of epidermolysis bullosa: 19 Oct 2020 (EU/3/20/2342)

Key Milestones in 2021-22



AMRYT PHARMA

GROWTH OPPORTUNITY

LEVERAGING OUR SIGNIFICANT INFRASTRUCTURE & EXPERTISE TO DRIVE FUTURE GROWTH

- Existing business is growing & significantly cash generative
- Potential to acquire further assets through in-licensing or M&A
- Full infrastructure in place - primed & ready to receive additional assets
- Experienced management team - proven track record of building a diversified rare disease product portfolio
- Offers significant economies of scale & synergy opportunities
- Proven track record of execution, integration, delivering synergies and driving growth
- Ready to launch Oleogel-S10 in Q4 2021, if approved
- Opportunity through BD to add products that will grow revenues, EBITDA and cash generation

Q4 AND FULL YEAR 2020 FINANCIALS

IFRS AND NON-GAAP ADJUSTED RESULTS – Q4 2020 EBITDA

US$M	Q4 2020 (unaudited)	Q4 2020 Non-cash Items[1]	Q4 2020 Non-GAAP Adjusted
Revenue	**42.5**	**-**	**42.5**
Cost of sales	(29.9)	17.3	(12.5)
Gross profit	**12.6**	**17.3**	**29.9**
R&D	(5.1)	-	(5.1)
SG&A	(19.8)	0.4	(19.4)
Acquisition & severance related costs	-	-	-
Share based compensation expenses	(1.6)	1.6	-
Operating (loss) / profit before finance expense	**(13.9)**	**19.3**	**5.4[2]**

1. Non-cash items include amortisation of the acquired metreleptin and lomitapide intangible assets ($10.7M), amortisation of the inventory fair value step-up that was acquired at the acquisition date ($6.6M), depreciation ($0.4M) and share based compensation expenses ($1.6M).

2. EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

IFRS AND NON-GAAP ADJUSTED RESULTS - FY 2020 EBITDA

US$M	FY 2020 (unaudited)	FY 2020 Non-cash Items[1]	FY 2020 Non-GAAP Adjusted
Revenue	**182.6**	**-**	**182.6**
Cost of sales	(119.0)	70.6	(48.4)
Gross profit	**63.6**	**70.6**	**134.2**
R&D	(27.6)	-	(27.6)
SG&A	(76.7)	1.5	(75.2)
Acquisition & severance related costs	(1.0)	-	(1.0)
Share based compensation expenses	(4.7)	4.7	-
Operating (loss) / profit before finance expense	**(46.4)**	**76.8**	**30.4[2]**

1. Non-cash items include amortisation of the acquired metreleptin and lomitapide intangible assets ($43.0M), amortisation of the inventory fair value step-up that was acquired at the acquisition date ($27.6M), depreciation ($1.5M) and share based compensation expenses ($4.7M).

2. EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

Questions & Answers

AMRYT PHARMA